Lakeland PeptidesPeptide therapy, explained · Lakeland & Polk County, FL

Peptide library

Tirzepatide: What Lakeland Readers Should Know

Also known as: Zepbound, Mounjaro, GIP/GLP-1, dual agonist

Not reviewed by a licensed provider. Read our disclaimer

Last updated

At a glance

Type
GIP and GLP-1 receptor agonist (dual agonist)
Human evidence
FDA-approved Approved by the FDA for specific uses after large clinical trials.
FDA status
FDA-approved (Zepbound, Mounjaro); compounded and online versions are not (as of October 1, 2026)
How it is given
Injection under the skin

Tirzepatide is the active ingredient in Zepbound and Mounjaro, prescription medicines made by Eli Lilly. It acts on two gut-hormone receptors instead of one. This page is general information, not advice for your situation.

What it is and how it works

Tirzepatide is a lab-made peptide that switches on two receptors: GLP-1 and GIP. Both are hormones your gut releases after you eat. A fatty side chain lets it attach to a blood protein called albumin, so it lasts long enough to be given once a week.1

According to its label, tirzepatide lowers how many calories people eat, helps the pancreas release insulin when blood sugar is high, and slows how fast food leaves the stomach. The weight lost is more fat than lean tissue.1

Tirzepatide is given as an injection under the skin once a week, starting low and raised in steps at least 4 weeks apart.1 This site does not give dosing.

What the research shows (and where evidence is weak)

Tirzepatide has been tested in large randomized controlled trials, which assign people by chance to the drug, a placebo (dummy shot) or another drug. These trials tested FDA-approved products, not compounded ones.

  • Weight, without diabetes. SURMOUNT-1 followed 2,539 adults with obesity, or overweight plus a weight-related condition, for 72 weeks. Average weight fell 15.0% to 20.9% depending on dose, versus 3.1% on placebo. On the two higher doses, 50% to 57% of people lost at least a fifth of their body weight, compared with 3% on placebo.2
  • Weight, with type 2 diabetes. People with diabetes lost less: 12.8% to 14.7%, versus 3.2% on placebo, in a 72-week trial of 938 adults.1
  • Compared with semaglutide. In SURMOUNT-5, 751 adults with obesity lost 20.2% on tirzepatide versus 13.7% on semaglutide over 72 weeks.3 In SURPASS-2, adults with type 2 diabetes had larger drops in HbA1c (a measure of average blood sugar) and lost 1.9 to 5.5 kg more weight than on semaglutide. That trial used a lower semaglutide dose than the one now used for weight loss.4
  • Sleep apnea. Two 52-week trials enrolled 469 adults with obesity and moderate to severe obstructive sleep apnea. Breathing pauses per hour of sleep fell by about 25 to 29 on tirzepatide versus about 5 on placebo.5
  • Heart events. In 13,299 adults with type 2 diabetes and heart disease followed for about 4 years, tirzepatide was at least as good as dulaglutide, another GLP-1 drug, at preventing heart attack, stroke and heart-related death. It was not shown to be better, and there was no placebo group.6

Where the evidence is weaker:

  • Stopping. In SURMOUNT-4, people first lost an average of 20.9% over 36 weeks. Those then switched to placebo regained weight, and their waist size grew by 7.8 cm, while those who stayed on the drug kept losing.1 On average, people who stopped regained weight. One analysis of six semaglutide and tirzepatide studies projected that about half the lost weight would return by about 7.5 months. Its estimates beyond one year are model-based.7
  • Who paid. Eli Lilly funded the main trials.23 SURMOUNT-5 and SURPASS-2 were “open-label,” meaning people knew which drug they were taking.34
  • Missing data. In SURMOUNT-1, final weights were missing for 21.6% of the placebo group and about 10% of the tirzepatide groups. Those values were estimated.1
  • Muscle. The label says more fat than lean tissue is lost. It does not say muscle is spared.1

FDA and regulatory status

As of labels revised in August 2026, tirzepatide is FDA-approved as:

  • Zepbound: with diet and activity, for long-term weight reduction in adults with obesity, or with overweight plus a weight-related condition, and for moderate to severe obstructive sleep apnea in adults with obesity.1
  • Mounjaro: for blood-sugar control in adults and children 10 and older with type 2 diabetes (children were added in December 2025), and to lower the risk of heart attack, stroke and heart-related death in adults with type 2 diabetes at high risk (added in August 2026).6

Compounding. FDA declared the tirzepatide shortage over in December 2024, after re-evaluating an October 2024 decision. The temporary grace periods for compounding pharmacies and outsourcing facilities ended in early 2025. As of April 2026, FDA said tirzepatide was on neither its drug shortage list nor the list of bulk substances outsourcing facilities may use.8 On April 30, 2026, FDA proposed formally excluding it from that list.9 As of November 13, 2026, we did not find a final FDA decision on that proposal. Check FDA’s announcement for updates.9 Compounded drugs are not FDA-approved.8 See our guide to compounded vs. FDA-approved peptides.

Fake and “research” products. FDA reports fraudulent “compounded” tirzepatide sold in the U.S. and has warned companies selling tirzepatide falsely labeled “for research purposes” or “not for human consumption.”10 Read more about research-chemical peptides.

Sport. The U.S. Anti-Doping Agency says GLP-1 medicines are not prohibited in sport.11

Common side effects and safety

In the weight trials, stomach and bowel side effects affected 56% of people on tirzepatide versus 30% on placebo, mostly while the dose was being raised. About 5% to 7% stopped because of side effects, versus 3.4% on placebo.1 Common effects include nausea, diarrhea, vomiting, constipation, stomach pain, indigestion, injection-site reactions, tiredness, allergic reactions, burping, hair loss and acid reflux.1

Both labels carry a boxed warning, FDA’s strongest kind. Tirzepatide caused thyroid C-cell tumors in rats. Whether it does in people is unknown. It should not be used by anyone with a personal or family history of medullary thyroid cancer or a condition called MEN 2.1

Other label warnings include severe stomach problems, kidney injury from dehydration, gallbladder problems, pancreatitis (an inflamed pancreas), serious allergic reactions, low blood sugar with insulin or certain diabetes pills, eye complications in type 2 diabetes (added in 2026), and breathing stomach contents into the lungs during anesthesia.1

The label says tirzepatide may harm a pregnancy. Birth-control pills may work less well for 4 weeks after starting and after each dose increase, so the label advises switching methods or adding a barrier method.1

As of May 31, 2026, FDA had received more than 730 adverse-event reports linked to compounded tirzepatide, which do not by themselves prove cause, and has warned about dosing errors.10

Typical cost range

As of November 12, 2026, Lilly listed these self-pay prices for Zepbound vials and pens, where a “month” is 28 days:12

  • Starting dose: $299 a month.
  • Second dose step: $399 a month.
  • Higher doses: $449 a month if refilled within 45 days; otherwise $499 to $699.

Lilly marks these “HSA/FSA eligible,” adding that eligibility may vary by plan. Prices change.12

Medicare. CMS says Part D plans must keep covering Zepbound for sleep apnea in adults with obesity.13 For weight management alone, a temporary program called the Medicare GLP-1 Bridge has offered certain GLP-1 drugs to eligible Part D members for a $50 copay since July 1, 2026. It runs through December 31, 2027.14

Mounjaro self-pay prices and local prices for compounded tirzepatide were not part of this research. Prices vary between pharmacies and clinics. Ask any provider for a written price breakdown before you start. See our cost guide and insurance, HSA and FSA guide.

Questions to ask a provider

  • Why tirzepatide instead of semaglutide, or the other way around, for me?
  • Is this Zepbound, Mounjaro or a compounded product? If compounded, why, and which state-licensed pharmacy makes it?
  • How will you check thyroid, pancreas, gallbladder and kidney risks first?
  • I use birth-control pills. What should I do?
  • What is the plan if I stop?
  • Will insurance or Medicare cover it for my diagnosis, and what is the full monthly cost?

Footnotes

  1. Eli Lilly and Company. ZEPBOUND (tirzepatide) injection: prescribing information. Revised August 2026. Accessed November 2026. https://uspl.lilly.com/zepbound/zepbound.html ↩ ↩2 ↩3 ↩4 ↩5 ↩6 ↩7 ↩8 ↩9 ↩10 ↩11 ↩12 ↩13

  2. Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387(3):205-216. https://doi.org/10.1056/NEJMoa2206038 ↩ ↩2

  3. Aronne LJ, Horn DB, le Roux CW, et al. Tirzepatide as compared with semaglutide for the treatment of obesity. N Engl J Med. 2025;393(1):26-36. https://doi.org/10.1056/NEJMoa2416394 ↩ ↩2 ↩3

  4. Frías JP, Davies MJ, Rosenstock J, et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. N Engl J Med. 2021;385(6):503-515. https://doi.org/10.1056/NEJMoa2107519 ↩ ↩2

  5. Malhotra A, Grunstein RR, Fietze I, et al. Tirzepatide for the treatment of obstructive sleep apnea and obesity. N Engl J Med. 2024;391(13):1193-1205. https://doi.org/10.1056/NEJMoa2404881 ↩

  6. Eli Lilly and Company. MOUNJARO (tirzepatide) injection: prescribing information. Revised August 2026. Accessed November 2026. https://uspl.lilly.com/mounjaro/mounjaro.html ↩ ↩2

  7. Kow CS, Thiruchelvam K, Ramachandram DS, et al. Weight regain trajectories after discontinuation of semaglutide or tirzepatide: a reconstructed aggregate-data Bayesian longitudinal meta-analysis. Endocrinol Diabetes Metab. 2026;9(5):e70325. https://doi.org/10.1002/edm2.70325 ↩

  8. U.S. Food and Drug Administration. FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize. Content current as of April 1, 2026. Accessed November 2026. https://www.fda.gov/drugs/drug-alerts-and-statements/fda-clarifies-policies-compounders-national-glp-1-supply-begins-stabilize ↩ ↩2

  9. U.S. Food and Drug Administration. FDA proposes to exclude semaglutide, tirzepatide, and liraglutide on 503B bulks list. Press release. April 30, 2026. Accessed November 2026. https://www.fda.gov/news-events/press-announcements/fda-proposes-exclude-semaglutide-tirzepatide-and-liraglutide-503b-bulks-list ↩ ↩2

  10. U.S. Food and Drug Administration. FDA’s concerns with unapproved GLP-1 drugs used for weight loss. Content current as of October 1, 2026. Accessed November 2026. https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss ↩ ↩2

  11. U.S. Anti-Doping Agency. Weight loss drugs: what athletes need to know about GLP-1s. Accessed November 2026. https://www.usada.org/spirit-of-sport/weight-loss-drugs-glp-1s/ ↩

  12. Eli Lilly and Company. LillyDirect: Zepbound (tirzepatide). Material code CMAT-05333 10/2026. Accessed November 12, 2026. https://www.lilly.com/lillydirect/zepbound ↩ ↩2

  13. Klomp C. Medicare GLP-1 Bridge: expectations and frequently asked questions for Part D sponsors. Centers for Medicare & Medicaid Services. June 10, 2026. Accessed November 2026. https://www.cms.gov/files/document/medicare-glp-1-bridge-expectations-faqs.pdf ↩

  14. Centers for Medicare & Medicaid Services. Medicare GLP-1 Bridge. Last modified July 13, 2026. Accessed November 2026. https://www.cms.gov/medicare/coverage/prescription-drug-coverage/medicare-glp-1-bridge ↩

Frequently asked questions

Is tirzepatide the same as Zepbound and Mounjaro?

Tirzepatide is the active ingredient in both. Zepbound is approved for long-term weight management and for sleep apnea in adults with obesity. Mounjaro is approved for type 2 diabetes and for lowering heart risk in some adults with type 2 diabetes.

How is tirzepatide different from semaglutide?

Semaglutide acts on one hormone receptor, GLP-1. Tirzepatide acts on GLP-1 and a second receptor called GIP. In one head-to-head trial paid for by tirzepatide's maker, people lost more weight on tirzepatide, but everyone knew which drug they were taking.

Is compounded tirzepatide still available?

FDA declared the tirzepatide shortage over in December 2024, and the grace periods for compounding pharmacies ended in early 2025. Compounded drugs are not FDA-approved, and FDA has warned about fake and mis-dosed products.

What happens if I stop taking tirzepatide?

On average, people who stopped regained weight, while people who kept taking it kept losing. One analysis estimated that about half the lost weight could return within about 7.5 months, but that is a model estimate.

Related goals

Questions? Talk to a licensed provider

See a free list of top rated clinics in Lakeland and Polk County, with their phone numbers and Google reviews. No one will call you.

Find a top rated provider
Find a top rated provider today